193 related articles for article (PubMed ID: 27493270)
1. Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
Blakkisrud J; Løndalen A; Martinsen AC; Dahle J; Holtedahl JE; Bach-Gansmo T; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):48-54. PubMed ID: 27493270
[TBL] [Abstract][Full Text] [Related]
2. Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
Blakkisrud J; Løndalen A; Dahle J; Turner S; Holte H; Kolstad A; Stokke C
J Nucl Med; 2017 Jan; 58(1):55-61. PubMed ID: 27587710
[TBL] [Abstract][Full Text] [Related]
3. Pre-dosing with lilotomab prior to therapy with
Stokke C; Blakkisrud J; Løndalen A; Dahle J; Martinsen ACT; Holte H; Kolstad A
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1233-1241. PubMed ID: 29470615
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate
Blakkisrud J; Holtedahl JE; Løndalen A; Dahle J; Bach-Gansmo T; Holte H; Nygaard S; Kolstad A; Stokke C
J Nucl Med; 2018 Apr; 59(4):704-710. PubMed ID: 28848035
[No Abstract] [Full Text] [Related]
5. FDG PET/CT and Dosimetric Studies of
Løndalen A; Blakkisrud J; Revheim ME; Dahle J; Kolstad A; Stokke C
Mol Imaging Biol; 2022 Oct; 24(5):807-817. PubMed ID: 35486292
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of
Løndalen A; Blakkisrud J; Revheim ME; Madsbu UE; Dahle J; Kolstad A; Stokke C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1902-1914. PubMed ID: 33196921
[TBL] [Abstract][Full Text] [Related]
7.
Malenge MM; Patzke S; Ree AH; Stokke T; Ceuppens P; Middleton B; Dahle J; Repetto-Llamazares AHV
J Nucl Med; 2020 Oct; 61(10):1468-1475. PubMed ID: 32245896
[TBL] [Abstract][Full Text] [Related]
8. Myelosuppression in patients treated with
Blakkisrud J; Løndalen A; Dahle J; Martinsen AC; Kolstad A; Stokke C
Acta Oncol; 2021 Nov; 60(11):1481-1488. PubMed ID: 34425735
[TBL] [Abstract][Full Text] [Related]
9. Combination of
Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
[TBL] [Abstract][Full Text] [Related]
10. Initial results for Hybrid SPECT--conjugate-view tumor dosimetry in 131I-anti-B1 antibody therapy of previously untreated patients with lymphoma.
Koral KF; Dewaraja Y; Li J; Barrett CL; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2000 Sep; 41(9):1579-86. PubMed ID: 10994741
[TBL] [Abstract][Full Text] [Related]
11. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response.
Sgouros G; Squeri S; Ballangrud AM; Kolbert KS; Teitcher JB; Panageas KS; Finn RD; Divgi CR; Larson SM; Zelenetz AD
J Nucl Med; 2003 Feb; 44(2):260-8. PubMed ID: 12571219
[TBL] [Abstract][Full Text] [Related]
12. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.
Kolstad A; Illidge T; Bolstad N; Spetalen S; Madsbu U; Stokke C; Blakkisrud J; Løndalen A; O'Rourke N; Beasley M; Jurczak W; Fagerli UM; Kaščák M; Bayne M; Obr A; Dahle J; Rojkjaer L; Pascal V; Holte H
Blood Adv; 2020 Sep; 4(17):4091-4101. PubMed ID: 32877524
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
Yadav MP; Singla S; Thakral P; Ballal S; Bal C
Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
[TBL] [Abstract][Full Text] [Related]
15. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma.
Ferrer L; Malek E; Bodet-Milin C; Legouill S; Prangère T; Robu D; Jeans S; Tipping J; Huglo D; Carpentier P; Illidge T; Kraeber-Boderé F; Morschhauser F; Bardiès M
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):529-37. PubMed ID: 23358406
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.
Dewaraja YK; Schipper MJ; Shen J; Smith LB; Murgic J; Savas H; Youssef E; Regan D; Wilderman SJ; Roberson PL; Kaminski MS; Avram AM
J Nucl Med; 2014 Jul; 55(7):1047-53. PubMed ID: 24842891
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
[TBL] [Abstract][Full Text] [Related]
18. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
19. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
20. Update on hybrid conjugate-view SPECT tumor dosimetry and response in 131I-tositumomab therapy of previously untreated lymphoma patients.
Koral KF; Dewaraja Y; Li J; Lin Q; Regan DD; Zasadny KR; Rommelfanger SG; Francis IR; Kaminski MS; Wahl RL
J Nucl Med; 2003 Mar; 44(3):457-64. PubMed ID: 12621015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]